Processa Pharmaceuticals, Inc.
PCSA
$1.99
-$0.17-7.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.16% | 20.94% | 55.36% | 60.66% | 11.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.87% | 17.01% | 35.37% | 1.87% | 28.19% |
| Operating Income | 40.87% | -17.01% | -35.37% | -1.87% | -28.19% |
| Income Before Tax | 16.99% | -19.15% | -23.10% | -1.53% | -30.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.99% | -19.15% | -23.10% | -1.53% | -30.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.99% | -19.15% | -23.10% | -1.53% | -30.68% |
| EBIT | 40.87% | -17.01% | -35.37% | -1.87% | -28.19% |
| EBITDA | 40.87% | -17.01% | -35.37% | -1.86% | -28.18% |
| EPS Basic | 81.03% | 83.01% | 92.33% | 93.00% | 75.20% |
| Normalized Basic EPS | 81.02% | 83.01% | 92.33% | 93.00% | 75.20% |
| EPS Diluted | 81.03% | 83.01% | 92.33% | 93.00% | 75.20% |
| Normalized Diluted EPS | 81.02% | 83.01% | 92.33% | 93.00% | 75.20% |
| Average Basic Shares Outstanding | 337.45% | 601.36% | 1,504.84% | 1,351.15% | 427.07% |
| Average Diluted Shares Outstanding | 337.45% | 601.36% | 1,504.84% | 1,351.15% | 427.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |